Tenecteplase versus alteplase for early treatment of ischaemic stroke

I read with interest the Article by Andrew Bivard and colleagues,1 which reported findings of the TASTE-A trial, comparing tenecteplase with alteplase for early reperfusion in the Melbourne Mobile Stroke Unit. The authors concluded that ultra-early tenecteplase treatment resulted in a greater reduction of the volume of post-treatment CT-perfusion lesion (primary endpoint) compared with alteplase. However, the findings elicit several concerns.